Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06)

BACKGROUND: S-1 plus cisplatin is a standard regimen for advanced gastric cancer (AGC) in Asia. The ToGA trial established a fluoropyrimidine plus cisplatin and trastuzumab as a standard treatment for human epidermal growth factor receptor 2 (HER2)-positive AGC. In the HERBIS-1 trial, trastuzumab co...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimura, Yutaka, Fujii, Masashi, Masuishi, Toshiki, Nishikawa, Kazuhiro, Kunisaki, Chikara, Matsusaka, Satoshi, Segawa, Yoshihiko, Nakamura, Masato, Sasaki, Kinro, Nagao, Narutoshi, Hatachi, Yukimasa, Yuasa, Yasuhiro, Asami, Shinya, Takeuchi, Masahiro, Furukawa, Hiroshi, Nakajima, Toshifusa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906490/
https://www.ncbi.nlm.nih.gov/pubmed/28936560
http://dx.doi.org/10.1007/s10120-017-0766-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906490/
https://www.ncbi.nlm.nih.gov/pubmed/28936560
http://dx.doi.org/10.1007/s10120-017-0766-x

Ejemplares similares